Hem (hBMMSC-EVs) in a rat model of ischemic brain injury. Methods: hBM-MSCs (Lonza) and hBM-MSC-EVs isolated from the culture media of these cells were employed in our research. 5 105 hBMMSCs labelled with superparamagnetic iron oxide nanoparticles conjugated with rhodamine (Molday ION, BioPAL) or 1.3 109 hBM-MSCEVs stained with lipophilic dye PKH26 (Sigma) have been transplanted in to the correct internal carotid artery of Wistar rats with focal brain Anti-Mullerian Hormone Receptor Type 2 Proteins Species injury brought on by stereotactic injection of 1 l/50nmol ouabain in to the right hemisphere, 48 h immediately after the ischemic insult. The inflow and localization of infused hBM-MSCs was monitored using MRI. On top of that, the presence of hBM-MSCs or hBM-MSC-EVs in rat brain was detected by confocal microscopy evaluation. The cellular and humoral immune response within the brain of experimental animals was evaluated immunohistochemically and with Bio-Plex ProTM Cytokine, Chemokine and Growth Factor Assay (BioRad). Results: We observed that both hBM-MSCs and hBM-MSC-EVs injected i.a. into focal brain injured rats migrated into insulted hemisphere and had been visible close to the lesion. Immunohistochemical analysis of unique cell subsets inside the rat brain revealed that transplantation of hBM-MSCs or hBM-MSC-EVs lowered the amount of activated astrocytes (GFAP+), microglia (ED1+) and leukocytes (CD45RA+) evoked by ischemia. Additionally, the decrease of pro-inflammatory cytokines, IL-1alfa, IL1beta, IL-6, IFN-, and chemokines, CXCL-1, MIP-1, MIP-3, MCP-1, immediately after 1, three and 7 days of hBM-MSCs or hBM-MSC-EVs infusion was observed in comparison to non-treated rats with ischemic brain injury. Summary/conclusion: Our evaluation reveals that hBM-MSCs and hBMMSC-EVs transplanted intra-arterially modulate immune response in rat brain caused by focal cerebral ischemia. Within this experimental model, hBM-MSC-derived EVs seem to possess exactly the same anti-inflammatory effects as their cells of origin. Funding: Supported by MMRC statutory grant no six.ISEV 2018 abstract bookSymposium Session three EVs as Therapeutic Agents Chairs: Yong Song Gho; Ewa Zuba Surma Place: Space 6 10:452:OT03.Extracellular vesicles released by E2 Enzymes Proteins custom synthesis mesenchymal stem cells represent a novel therapeutic alternative in systemic sclerosis Pauline Rozier1; Marie Maumus1; Alexandre Maria2; Karine Toupet3; Christian Jorgensen3; Philippe Guilpain3; Daniele Noel1Inserm, Montpellier, France; 2CHU Montpellier, Montpellier, France; UniversitMontpellier, Montpellier, FranceBackground: Systemic sclerosis (SSc) is actually a uncommon intractable autoimmune disease, with unmet medical require. Cell therapy working with mesenchymal stem cells (MSC) is a promising approach, and we lately reported its efficacy inside a murine model of SSc induced by hypochlorite (HOCl). Given that MSC act primarily by way of the secretion of soluble factors released inside extracellular vesicles (EV), the usage of EV rather of cells seems an desirable alternative. Herein, we compared the effects of two kinds of EV, exosomes and microparticles, in HOCl-induced SSc. Approaches: BALB/c mice have been challenged with every day intradermal HOCl injections for six weeks to induce SSc. Every group was treated at midexperiment with infusions of 2.five 105 murine MSC, 250 ng of exosomes or microparticles isolated from IFN-activated or non-activated (NA) MSC. We measured skin thickness just about every week. At euthanasia (d42), we analysed the expression of fibrotic and inflammatory markers (collagens 1 and three, Sma, TGF, MMP 1 and 9, TIMP1, IL1, IL6, TNF) in lungs and skin samples making use of RT-qPCR. Resu.